National Law Firms Calls for More FDA Action on Actos Bladder Cancer Threat

National Law Firms Calls for More FDA Action on Actos Bladder Cancer Threat

National Law Firms Calls for More FDA Action on Actos Bladder Cancer Threat

A national law firm is not satisfied with the way the U.S. Food & Drug Administration (FDA) has handled warnings regarding Actos (pioglitazone) bladder cancer risks. In a statement published today, Parker Waichman LLP called on the FDA to compel Takeda Pharmaceuticals, the maker of the type 2 diabetes drug, to issues its own Actos bladder cancer warning to doctors in the U.S. Takeda recently sent such a warning to providers in Canada, in collaboration with that country’s FDA counterpart, Health Canada.

Last June, the FDA did issue a Drug Safety Communication regarding Actos and bladder cancer. In the communication, the FDA announced that new information about this risk was being added to the “Warnings and Precautions” section of the Actos label. However, Takeda did not issue its own statement at the time.

© 2005-2017 Parker Waichman LLP ®. All Rights Reserved.